Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Published On 2025-07-30 09:00 GMT   |   Update On 2025-07-30 09:00 GMT
Advertisement

Ahmedabad: Zydus Lifesciences Limited has announced the completion of the acquisition of an 85.6 percent stake in Amplitude Surgical.

The deal follows agreements signed on March 11, 2025, between Zydus Lifesciences and PAI, along with two minority shareholders of Amplitude Surgical to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights at a price of €6.25 per share and a total consideration of €256mn (the “Block Acquisition”).  

As all conditions precedent to the completion have now been fulfilled, and the Block Acquisition has been subsequently completed on July 29, 2025, Zydus now holds 85.6% of the share capital and voting rights of Amplitude Surgical.

Olivier Jallabert will remain in his role as CEO of Amplitude Surgical, and, as part of the Block Acquisition, has invested into the company which has completed the Block Acquisition.

Advertisement

In the context of the Block Acquisition, Amplitude Surgical has terminated with effect as of July 28, 2025 its liquidity contract entered into between Amplitude Surgical, Oddo BHF and Natixis dated June 19, 2018.

Zydus will file a simplified mandatory tender offer (the “Offer”) on July 30, 2025 for all the remaining outstanding shares of Amplitude Surgical at a price of €6.25 per share, at par with the price paid for the Block Acquisition.

Considering the certain undertakings to tender received from seven shareholders representing in aggregate 4.7% of share capital and voting rights, Zydus will be able to secure more than 90% of the capital and voting rights of Amplitude Surgical upon completion of the Offer and will subsequently request the implementation of a squeeze-out.

Subject to the French Financial Market Authority’s (Autorité des marches financiers, AMF) clearance of the Offer, it is currently envisaged that the Offer may be opened in September 2025. No other regulatory approval will be required.

On July 28, 2025, the Board of Directors of Amplitude Surgical unanimously welcomed the Offer and on the same date issued its reasoned opinion following receipt of the fairness opinion from Finexsi, appointed as independent expert for the purpose of the Offer.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News